Amiodarone treatment in patients with ventricular arrhythmias

E. N. Prystowsky, J. J. Heger, W. M. Miles, D. P. Zipes

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Amidarone has been used in the therapy of supraventricular and ventricular tachycardia, and has often been categorised as a class III rather than a class I agent. However, in patients with ventricular arrhythmias, amiodarone 800 mg daily for 14 days prolonged the right ventricular effective refractory period by a mean of 18.8 msec (p < 0.05), and HV interval by a mean of 5.2 msec (p < 0.05), these changes being similar to those noted with drugs such as quinidine, procainamide, disopyramide and encainide. The antiarrhythmic efficacy of amiodarone was evaluated in 196 patients with recurrent sustained ventricular tachycardia, recurrent ventricular fibrillation or recurrent nonsustained ventricular tachycardia. Coronary artery disease, dilated (congestive) cardiomyopathy, or other forms of heart disease were present in most patients. After 1 month of therapy, 177 patients continued to receive amiodarone and, during the remainder of the follow-up period, 139 patients had no recurrence of spontaneous ventricular tachycardia of ventricular fibrillation. Sudden cardiac death occurred in 15 patients after a mean treatment period of 10.4 months. Overall, amiodarone was an effective form of therapy in patients with ventricular tachycardia and ventricular fibrillation.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalDrugs
Volume29
Issue numberSUPPL. 3
StatePublished - 1985

Fingerprint

Amiodarone
Cardiac Arrhythmias
Ventricular Tachycardia
Ventricular Fibrillation
Encainide
Disopyramide
Procainamide
Dilated Cardiomyopathy
Quinidine
Therapeutics
Refractory materials
Supraventricular Tachycardia
Sudden Cardiac Death
Coronary Artery Disease
Heart Diseases
Pharmaceutical Preparations
Recurrence

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Prystowsky, E. N., Heger, J. J., Miles, W. M., & Zipes, D. P. (1985). Amiodarone treatment in patients with ventricular arrhythmias. Drugs, 29(SUPPL. 3), 47-52.

Amiodarone treatment in patients with ventricular arrhythmias. / Prystowsky, E. N.; Heger, J. J.; Miles, W. M.; Zipes, D. P.

In: Drugs, Vol. 29, No. SUPPL. 3, 1985, p. 47-52.

Research output: Contribution to journalArticle

Prystowsky, EN, Heger, JJ, Miles, WM & Zipes, DP 1985, 'Amiodarone treatment in patients with ventricular arrhythmias', Drugs, vol. 29, no. SUPPL. 3, pp. 47-52.
Prystowsky EN, Heger JJ, Miles WM, Zipes DP. Amiodarone treatment in patients with ventricular arrhythmias. Drugs. 1985;29(SUPPL. 3):47-52.
Prystowsky, E. N. ; Heger, J. J. ; Miles, W. M. ; Zipes, D. P. / Amiodarone treatment in patients with ventricular arrhythmias. In: Drugs. 1985 ; Vol. 29, No. SUPPL. 3. pp. 47-52.
@article{1e2f207bd4924461a6323fe61e2cd90c,
title = "Amiodarone treatment in patients with ventricular arrhythmias",
abstract = "Amidarone has been used in the therapy of supraventricular and ventricular tachycardia, and has often been categorised as a class III rather than a class I agent. However, in patients with ventricular arrhythmias, amiodarone 800 mg daily for 14 days prolonged the right ventricular effective refractory period by a mean of 18.8 msec (p < 0.05), and HV interval by a mean of 5.2 msec (p < 0.05), these changes being similar to those noted with drugs such as quinidine, procainamide, disopyramide and encainide. The antiarrhythmic efficacy of amiodarone was evaluated in 196 patients with recurrent sustained ventricular tachycardia, recurrent ventricular fibrillation or recurrent nonsustained ventricular tachycardia. Coronary artery disease, dilated (congestive) cardiomyopathy, or other forms of heart disease were present in most patients. After 1 month of therapy, 177 patients continued to receive amiodarone and, during the remainder of the follow-up period, 139 patients had no recurrence of spontaneous ventricular tachycardia of ventricular fibrillation. Sudden cardiac death occurred in 15 patients after a mean treatment period of 10.4 months. Overall, amiodarone was an effective form of therapy in patients with ventricular tachycardia and ventricular fibrillation.",
author = "Prystowsky, {E. N.} and Heger, {J. J.} and Miles, {W. M.} and Zipes, {D. P.}",
year = "1985",
language = "English",
volume = "29",
pages = "47--52",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Amiodarone treatment in patients with ventricular arrhythmias

AU - Prystowsky, E. N.

AU - Heger, J. J.

AU - Miles, W. M.

AU - Zipes, D. P.

PY - 1985

Y1 - 1985

N2 - Amidarone has been used in the therapy of supraventricular and ventricular tachycardia, and has often been categorised as a class III rather than a class I agent. However, in patients with ventricular arrhythmias, amiodarone 800 mg daily for 14 days prolonged the right ventricular effective refractory period by a mean of 18.8 msec (p < 0.05), and HV interval by a mean of 5.2 msec (p < 0.05), these changes being similar to those noted with drugs such as quinidine, procainamide, disopyramide and encainide. The antiarrhythmic efficacy of amiodarone was evaluated in 196 patients with recurrent sustained ventricular tachycardia, recurrent ventricular fibrillation or recurrent nonsustained ventricular tachycardia. Coronary artery disease, dilated (congestive) cardiomyopathy, or other forms of heart disease were present in most patients. After 1 month of therapy, 177 patients continued to receive amiodarone and, during the remainder of the follow-up period, 139 patients had no recurrence of spontaneous ventricular tachycardia of ventricular fibrillation. Sudden cardiac death occurred in 15 patients after a mean treatment period of 10.4 months. Overall, amiodarone was an effective form of therapy in patients with ventricular tachycardia and ventricular fibrillation.

AB - Amidarone has been used in the therapy of supraventricular and ventricular tachycardia, and has often been categorised as a class III rather than a class I agent. However, in patients with ventricular arrhythmias, amiodarone 800 mg daily for 14 days prolonged the right ventricular effective refractory period by a mean of 18.8 msec (p < 0.05), and HV interval by a mean of 5.2 msec (p < 0.05), these changes being similar to those noted with drugs such as quinidine, procainamide, disopyramide and encainide. The antiarrhythmic efficacy of amiodarone was evaluated in 196 patients with recurrent sustained ventricular tachycardia, recurrent ventricular fibrillation or recurrent nonsustained ventricular tachycardia. Coronary artery disease, dilated (congestive) cardiomyopathy, or other forms of heart disease were present in most patients. After 1 month of therapy, 177 patients continued to receive amiodarone and, during the remainder of the follow-up period, 139 patients had no recurrence of spontaneous ventricular tachycardia of ventricular fibrillation. Sudden cardiac death occurred in 15 patients after a mean treatment period of 10.4 months. Overall, amiodarone was an effective form of therapy in patients with ventricular tachycardia and ventricular fibrillation.

UR - http://www.scopus.com/inward/record.url?scp=0021919033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021919033&partnerID=8YFLogxK

M3 - Article

C2 - 3996245

AN - SCOPUS:0021919033

VL - 29

SP - 47

EP - 52

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - SUPPL. 3

ER -